Pipeline

Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for autoimmune diseases and cancer. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.

Asset Name	CAR Target/ Product Profile	Indication	Pre clinical	Phase 1	Phase 2/ Registrational
Autoimmunity
FT819 (CDRP)	CD19	SLE – Lupus Nephritis (LN) (RMAT)	FT819-201 (RECLAIM-LN)		NCT07570862
		FT819	CD19	SLE – Extra Renal (RMAT)	FT819-102	NCT06308978
		FT819	CD19	Systemic Sclerosis, Vasculitis & Myositis	FT819-102	NCT06308978
FT839	CD19/CD38^{1, 2}	Multiple indications, including RA	FT839-101 (COMPLETE)
FT522	CD19¹	Multiple indications, with mAb combination	FT522-102
Oncology
FT825	HER2¹	HER2 Positive Solid Tumor(s)	FT825-101		NCT06241456
Undisclosed			Ongoing R&D activity
FT836	MICA/B¹	Pan-tumor indications, including CRC	FT836-101 (PANACEA)		NCT07216105
FT836	MICA/B¹	Multiple Myeloma	FT836-IIT		NCT07221032
FT839	CD19/CD38^{1, 2}	Hematological Malignancies	IIT Initiation
Regenerative Medicine Product Concepts
FT-RegMed	iPSC derived cell types	Cell Replacement & Cell Factories	Ongoing R&D activity

Autoimmunity

Program	CAR Target/Product Profile	Indication	Phase
FT819 (CDRP)	CD19	SLE – Lupus Nephritis (LN) (RMAT)	Ph 2 FT819-201 (RECLAIM-LN)NCT07570862
		FT819	CD19	SLE – Extra Renal (RMAT)	Ph 1 FT819-102NCT06308978
		FT819	CD19	Systemic Sclerosis, Vasculitis & Myositis	Ph 1 FT819-102NCT06308978
FT839	CD19/CD38^{1, 2}	Multiple indications, including RA	Ph 1 FT839-101 (COMPLETE)
FT522	CD19¹	Multiple indications, with mAb combination	Ph 1 FT522-102

Oncology

Program	CAR Target/Product Profile	Indication	Phase
FT825	HER2	HER2 Positive Solid Tumor(s)	Ph 1 FT825-101NCT06241456
Undisclosed			Ph 1 Ongoing R&D activity
FT836	MICA/B¹	Pan-tumor indications, including CRC	Ph 1 FT836-101 (PANACEA)NCT07216105
FT836	MICA/B¹	Multiple Myeloma	Ph 1 FT836-IITNCT07221032
FT839	CD19/CD38^{1, 2}	Hematological Malignancies	Ph 1 IIT Initiation

Regenerative Medicine Product Concepts

Program	CAR Target/Product Profile	Indication	Phase
FT-RegMed	iPSC derived cell types	Cell Replacement & Cell Factories	Ph 1 Ongoing R&D activity

Product contains hnCD16 that allows combination with licensed monoclonal antibodies, i.e. anti-CD20 to extend antigen targeting capability
Product contains CD3 fusion receptor that allows combination with licensed T cell engagers, i.e. anti-BCMA and anti-GPRC5D to extend antigen targeting capability

CDRP: Chemistry, Manufacturing, and Controls Development and Readiness Pilot; CRC: colorectal cancer; RA: rheumatoid arthritis; RMAT: FDA Regenerative Medicine Advanced Therapy (RMAT) received in active moderate-to-severe SLE with or without LN; SLE: systemic lupus erythematosus; IIT: investigator initiated trial; Worldwide rights to FT819, FT836, FT839, FT522 and FT-RegMed